Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats

Diabetes Research and Clinical Practice

Volumn 92, Issue 2, 2011, Pages 213-222

  Han, Seung Jin ^a,b   Choi, Sung E ^a   Kang, Yup ^a   Jung, Jong Gab ^a   Yi, Sang A ^a   Kim, Hae Jin ^a   Lee, Kwan Woo ^a   Kim, Dae Jung ^a  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Cell; Islets of Langerhans; Metformin; Sitagliptin

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; SITAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL TRANSLOCATION GENE 1; BACULOVIRAL IAP REPEAT CONTAINING 5 GENE; BCL2 LIKE 1 GENE; CASPASE 8 GENE; CELL GROWTH; CELL SURVIVAL; CLUSTERIN GENE; CONTROLLED STUDY; DEFENDER AGAINST CELL DEATH 1 GENE; DEOXYRIBONUCLEASE I GENE; DIABETES MELLITUS; DOWN REGULATION; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN LIKE GROWTH FACTOR 1 GENE; INSULIN RELEASE; MALE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RAT; TRANSCRIPTION INITIATION; ZUCKER DIABETIC FATTY RAT;

ANIMALS; CASPASE 3; ETS-DOMAIN PROTEIN ELK-1; FLUORESCENT ANTIBODY TECHNIQUE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; METFORMIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRAZINES; RATS; RATS, ZUCKER; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES;

EID: 79955821979     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.01.016     Document Type: Article

References (35)

1. Porte D. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991, 40:166-180.
2. Butler A.E., Janson J., Soeller W.C., Butler P.C. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003, 52:2304-2314.
3. Deacon C.F., Holst J.J. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun 2002, 294:1-4.
4. Mest H.J., Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005, 48:616-620.
5. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
6. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diab Care 2006, 29:2638-2643.
7. Ahren B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diab Care 2004, 27:2874-2880.
8. Bosi E., Camisasca R.P., Collober C., Rochotte E., Garber A.J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diab Care 2007, 30:890-895.
9. Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diab Obes Metab 2007, 9:186-193.
10. DeFronzo R.A., Hissa M.N., Garber A.J., Luiz Gross J., Yuyan Duan R., Ravichandran S., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diab Care 2009, 32:1649-1655.
11. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition+metformin. Vasc Health Risk Manage 2008, 4:383-394.
12. Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., Pierazzuoli E., et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diab Care 2001, 24:489-494.
13. Lindsay J.R., Duffy N.A., McKillop A.M., Ardill J., O'Harte F.P., Flatt P.R., et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diab Med 2005, 22:654-657.
14. Coskun O., Kanter M., Korkmaz A., Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 2005, 51:117-123.
15. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
16. George M., Ayuso E., Casellas A., Costa C., Devedjian J.C., Bosch F. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 2002, 109:1153-1163.
17. Casellas A., Salavert A., Agudo J., Ayuso E., Jimenez V., Moya M., et al. Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes. Diabetes 2006, 55:3246-3255.
18. Butler P.C., Meier J.J., Butler A.E., Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007, 3:758-768.
19. Agudo J., Ayuso E., Jimenez V., Salavert A., Casellas A., Tafuro S., et al. IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia 2008, 51:1862-1872.
20. Frohman L.A., Downs T.R., Heimer E.P., Felix A.M. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989, 83:1533-1540.
21. Bergman A.J., Stevens C., Zhou Y., Yi B., Laethem M., De Smet M., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006, 28:55-72.
22. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diab Care 2007, 30:1335-1343.
23. Cornu M., Yang J.Y., Jaccard E., Poussin C., Widmann C., Thorens B. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 2009, 58:1816-1825.
24. Parczyk K., Pilarsky C., Rachel U., Koch-Brandt C. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 1994, 120:186-188.
25. Oda T., Pasinetti G.M., Osterburg H.H., Anderson C., Johnson S.A., Finch C.E. Purification and characterization of brain clusterin. Biochem Biophys Res Commun 1994, 204:1131-1136.
26. Kang S.W., Lim S.W., Choi S.H., Shin K.H., Chun B.G., Park I.S., et al. Antisense oligonucleotide of clusterin mRNA induces apoptotic cell death and prevents adhesion of rat ASC-17D Sertoli cells. Mol Cells 2000, 10:193-198.
27. Kim B.M., Han Y.M., Shin Y.J., Min B.H., Park I.S. Clusterin expression during regeneration of pancreatic islet cells in streptozotocin-induced diabetic rats. Diabetologia 2001, 44:2192-2202.
28. Dohi T., Salz W., Costa M., Ariyan C., Basadonna G.P., Altieri D.C. Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Rep 2006, 7:438-443.
29. Polzar B., Peitsch M.C., Loos R., Tschopp J., Mannherz H.G. Overexpression of deoxyribonuclease I (DNase I) transfected into COS-cells: its distribution during apoptotic cell death. Eur J Cell Biol 1993, 62:397-405.
30. Bernal-Mizrachi E., Wen W., Srinivasan S., Klenk A., Cohen D., Permutt M.A. Activation of Elk-1, an Ets transcription factor, by glucose and EGF treatment of insulinoma cells. Am J Physiol Endocrinol Metab 2001, 281:E1286-E1299.
31. Irako T., Akamizu T., Hosoda H., Iwakura H., Ariyasu H., Tojo K., et al. Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia 2006, 49:1264-1273.
32. Granata R., Settanni F., Biancone L., Trovato L., Nano R., Bertuzzi F., et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3′,5′-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology 2007, 148:512-529.
33. Yeh H.J., He Y.Y., Xu J., Hsu C.Y., Deuel T.F. Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. J Neurosci 1998, 18:3699-3707.
34. Perez-Pinera P., Chang Y., Deuel T.F. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 2007, 6:2877-2883.
35. Mehrabian M., Schulthess F.T., Nebohacova M., Castellani L.W., Zhou Z., Hartiala J., et al. Identification of ALOX5 as a gene regulating adiposity and pancreatic function. Diabetologia 2008, 51:978-988.